Patents by Inventor John G. Devane
John G. Devane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170000783Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers at least one active ingredient in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition.Type: ApplicationFiled: June 27, 2016Publication date: January 5, 2017Inventors: John G. Devane, Paul Stark, Niall M.M. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20130011447Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
-
Patent number: 8293277Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: GrantFiled: June 22, 1999Date of Patent: October 23, 2012Assignee: Alkermes Pharma Ireland LimitedInventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
-
Patent number: 8236352Abstract: The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.Type: GrantFiled: November 5, 2003Date of Patent: August 7, 2012Assignee: Alkermes Pharma Ireland LimitedInventors: H. William Bosch, Niels P. Ryde, Rajeev A. Jain, Jon Swanson, Robert Hontz, John G. Devane, Kenneth Ian Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
-
Patent number: 8119163Abstract: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.Type: GrantFiled: February 5, 2007Date of Patent: February 21, 2012Assignee: Alkermes Pharma Ireland LimitedInventors: John G Devane, Paul Stark, Niall M. N. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20110300210Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: May 6, 2011Publication date: December 8, 2011Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
-
Publication number: 20110064803Abstract: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.Type: ApplicationFiled: May 9, 2006Publication date: March 17, 2011Applicant: ELAN PHARMA INTERNATIONAL LIMITED.Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
-
Publication number: 20110008435Abstract: The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.Type: ApplicationFiled: February 7, 2007Publication date: January 13, 2011Applicant: Elan Corporation plcInventors: John G. Devane, Paul Stark, Niall M.M. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20100247636Abstract: The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.Type: ApplicationFiled: June 30, 2006Publication date: September 30, 2010Applicant: Elan Corporation, plcInventors: John G. Devane, Paul Stark, Niall M.M. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20100136106Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers famciclovir in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment or suppression of viral infections.Type: ApplicationFiled: June 7, 2006Publication date: June 3, 2010Inventors: Gary Liversidge, Scott Jenkins, John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi
-
Publication number: 20090297597Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.Type: ApplicationFiled: June 9, 2006Publication date: December 3, 2009Inventors: Gary Liversidge, Scott Jenkins, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, John G. Devane
-
Publication number: 20090297602Abstract: The invention relates to a modified release composition comprising loxoprofen or a salt or derivative thereof that in operation delivers the drug in a pulsatile or continuous manner for the treatment of pain and/or inflammation. The composition may comprise a first loxoprofen component and one subsequent loxoprofen component, wherein the first loxoprofen component comprises an immediate release component and the subsequent loxoprofen component comprises a modified release component.Type: ApplicationFiled: May 9, 2006Publication date: December 3, 2009Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Grvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
-
Publication number: 20090297619Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: June 11, 2009Publication date: December 3, 2009Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
-
Publication number: 20090062242Abstract: Methods and compositions for treating a condition involving gastrointestinal symptoms comprising administering to a patient in need of such treatment an effective amount of a P-glycoprotein substrate, wherein the P-glycoprotein substrate is a compound exhibiting an efflux inhibition ratio (EIR) of greater than or equal to 0.4, wherein the P-glycoprotein substrate is administered in a manner to minimize bioavailability.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: AGI Therapeutics plcInventor: John G. DEVANE
-
Publication number: 20080279929Abstract: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.Type: ApplicationFiled: February 5, 2007Publication date: November 13, 2008Applicant: Elan Corproation plcInventors: John G. Devane, Paul Stark, Nial M. N. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080248123Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: March 26, 2008Publication date: October 9, 2008Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
-
Publication number: 20080124393Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: October 31, 2007Publication date: May 29, 2008Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
-
Publication number: 20080118556Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers a combination of carbidopa, levodopa and entacapone in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment of Parkinson's disease.Type: ApplicationFiled: June 5, 2006Publication date: May 22, 2008Applicant: Elan Corporation, plcInventors: John G. Devane, Paul Stark, Niall M. M. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott A. Jenkins
-
Publication number: 20080113025Abstract: The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.Type: ApplicationFiled: June 25, 2007Publication date: May 15, 2008Applicant: Elan Pharma International LimitedInventors: John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080102121Abstract: The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.Type: ApplicationFiled: June 25, 2007Publication date: May 1, 2008Applicant: Elan Pharma International LimitedInventors: John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge